Media stories about Davita (NYSE:DVA) have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Davita earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.8469003560816 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Davita stock traded down $1.05 during midday trading on Thursday, hitting $65.79. 1,635,049 shares of the stock were exchanged, compared to its average volume of 1,558,910. Davita has a twelve month low of $52.51 and a twelve month high of $80.71. The company has a current ratio of 2.88, a quick ratio of 2.82 and a debt-to-equity ratio of 1.87. The firm has a market capitalization of $12,079.34, a PE ratio of 19.13, a P/E/G ratio of 0.96 and a beta of 1.03.

Davita (NYSE:DVA) last posted its earnings results on Tuesday, February 13th. The company reported $0.92 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.02). Davita had a return on equity of 12.86% and a net margin of 4.65%. The firm had revenue of $2.78 billion for the quarter, compared to analyst estimates of $3.90 billion. During the same period in the previous year, the firm posted $0.98 earnings per share. equities analysts forecast that Davita will post 4.15 earnings per share for the current fiscal year.

DVA has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of Davita from $4.90 to $84.00 and gave the company a “strong-buy” rating in a research report on Thursday, December 7th. Citigroup raised shares of Davita from a “neutral” rating to a “buy” rating and lifted their price target for the company from $67.71 to $82.00 in a research report on Monday, December 11th. Robert W. Baird reaffirmed a “buy” rating and set a $95.00 price target (up from $82.00) on shares of Davita in a research report on Friday, January 12th. SunTrust Banks set a $70.00 price target on shares of Davita and gave the company a “hold” rating in a research report on Thursday, December 7th. Finally, Raymond James Financial raised shares of Davita from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $65.00 to $84.00 in a research report on Thursday, December 7th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company. Davita presently has an average rating of “Hold” and a consensus price target of $79.30.

In other news, insider James K. Hilger sold 3,572 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $78.95, for a total transaction of $282,009.40. Following the transaction, the insider now directly owns 33,649 shares of the company’s stock, valued at $2,656,588.55. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Davita (DVA) Earning Somewhat Positive Media Coverage, Accern Reports” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at

About Davita

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Insider Buying and Selling by Quarter for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with's FREE daily email newsletter.